Dashboard
Manage Tickers

BIOA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

bioage-labs-q3-eps-056-beats-058-estimate-sales-2054m
Bioage Labs Q3 EPS $(0.56) Beats $(0.58) E...
11/06/2025 22:05:46

Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.58) b...

citigroup-maintains-buy-on-bioage-labs-raises-price-target-to-15
Citigroup Maintains Buy on Bioage Labs, Ra...
10/29/2025 19:55:30

Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and raises the price target from $10 to $15.

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/23/2025 17:07:13

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/23/2025 12:07:49

this-badger-meter-analyst-turns-bullish-here-are-top-4-upgrades-for-wednesday
This Badger Meter Analyst Turns Bullish; H...
10/22/2025 13:25:40

citigroup-upgrades-bioage-labs-to-buy-raises-price-target-to-10
Citigroup Upgrades Bioage Labs to Buy, Rai...
10/22/2025 11:21:41

Citigroup analyst Samantha Semenkow upgrades Bioage Labs (NASDAQ:BIOA) from Neutral to Buy and raises the price target from ...

bioage-labs-announces-first-participant-dosed-in-phase-1-clinical-trial-evaluating-bge-102-orally-available-small-molecule-nlrp3-inhibitor-for-treatment-of-obesity
BioAge Labs Announces First Participant Do...
08/15/2025 13:05:59

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available sm...

bioage-labs-q2-eps-060-misses-045-estimate
Bioage Labs Q2 EPS $(0.60) Misses $(0.45) ...
08/06/2025 21:13:49

Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.45)...

reported-saturday-bioage-labs-presents-preclinical-data-showing-apj-agonism-enhances-glycemic-control-and-cardioprotection-in-diabetic-obesity-and-hfpef
Reported Saturday, BioAge Labs Presents Pr...
06/23/2025 07:58:36

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benef...

bioage-labs-to-profile-17000-hunt-biobank-samples-in-norway-to-accelerate-aging-related-drug-target-discovery
BioAge Labs To Profile 17,000+ HUNT Bioban...
06/17/2025 13:07:15

Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate disco...

bioage-labs-completes-ind-enabling-studies-for-bge-102-and-advances-candidate-toward-clinic
BioAge Labs Completes IND-Enabling Studies...
05/29/2025 13:04:32

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year endBGE-102 induced weight loss in preclinical obe...

bioage-labs-q1-eps-036-beats-053-estimate-sales-145m
Bioage Labs Q1 EPS $(0.36) Beats $(0.53) E...
05/06/2025 21:02:12

Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.53) b...

citigroup-maintains-neutral-on-bioage-labs-lowers-price-target-to-5
Citigroup Maintains Neutral on Bioage Labs...
03/24/2025 14:41:28

Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Neutral and lowers the price target from $7 t...

bioage-labs-fy24-eps-663-up-from-3817-yoy
BioAge Labs FY24 EPS $(6.63) Up From $(38....
03/20/2025 20:33:13

Full Year 2024 Financial ResultsResearch and development expenses were $59.0 million for the year ended December 31, 2024, comp...

morgan-stanley-assumes-bioage-labs-at-underweight-announces-price-target-of-5
Morgan Stanley Assumes Bioage Labs at Unde...
03/07/2025 17:11:14

Morgan Stanley analyst Jeffrey Hung assumes Bioage Labs (NASDAQ:BIOA) with a Underweight rating and announces Price Target o...

Core News & Articles
BioArctic And Eisai's Lecanemab Denied By ...
03/03/2025 09:05:04

BioArctic AB's  partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the...

william-blair-initiates-coverage-on-bioage-labs-with-market-perform-rating
William Blair Initiates Coverage On Bioage...
02/28/2025 12:04:19

William Blair analyst Andy Hsieh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Market Perform rating.

bioage-discontinues-azelaprag-due-to-liver-issues-advances-next-gen-apj-agonists-nominates-nlrp3-inhibitor-bge-102-phase-1-data-expected-by-end-2025
BioAge Discontinues Azelaprag Due To Liver...
01/28/2025 14:03:22

Advancement of next-generation APJ agonists with discontinuation of azelapragNomination of NLRP3 inhibitor BGE-102 as a develop...

Core News & Articles
BioAge Labs Announces Multi-Year Collabora...
12/18/2024 14:01:04

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
12/09/2024 21:05:43

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION